Putting innovation at the heart of RNA-based therapeutics
Working towards a crucial breakthrough in the way we treat disease: HAYA Therapeutics aims to revolutionise patients treatments by focusing on Dark Genome-derived RNAs, now recognised as the ‹Regulatory Genome› RNAs. Thanks to its innovative approach, the company has attracted the attention of American pharmaceutical giant Eli Lilly. HAYA Therapeutics, which is supported by Innosuisse, is capitalising on this momentum to propel its technology to the forefront of the international scene and transform the treatment of certain diseases, while helping to increase health span.